Weekly Cardiology Research Analysis
This week was dominated by large, practice‑impacting cardiology studies that advance cardiorenal therapeutics, imaging-driven risk stratification, and pragmatic digital interventions. An IPD pooled analysis in Lancet establishes finerenone as a broadly beneficial therapy across CKD etiologies with consistent kidney and cardiovascular protection. Mechanistic-translational work identifies the ALOX5–ACSL4 ferroptosis axis as a druggable driver of calcific aortic valve disease, and imaging/diagnosti
Summary
This week was dominated by large, practice‑impacting cardiology studies that advance cardiorenal therapeutics, imaging-driven risk stratification, and pragmatic digital interventions. An IPD pooled analysis in Lancet establishes finerenone as a broadly beneficial therapy across CKD etiologies with consistent kidney and cardiovascular protection. Mechanistic-translational work identifies the ALOX5–ACSL4 ferroptosis axis as a druggable driver of calcific aortic valve disease, and imaging/diagnostic studies (cardiac CT in stroke pathways, OCT residual lipid burden, subendocardial PET metrics) refine detection and prognostication. Collectively, findings support expanding mineralocorticoid receptor antagonism in CKD, testing ALOX5-targeted strategies for aortic stenosis, and operationalizing imaging plus digital workflows into clinical practice.
Selected Articles
1. Efficacy and safety of finerenone in patients with chronic kidney disease: an individual participant data pooled analysis (INFINITY).
An individual participant data meta-analysis of three randomized, double-blind, placebo-controlled trials (n=14,574) found finerenone reduced CKD progression (including kidney failure), heart failure hospitalization, cardiovascular death, and all-cause mortality across diverse CKD etiologies and across glycemia, eGFR, and albuminuria strata.
Impact: IPD meta-analysis elevates finerenone as a foundational, disease‑modifying therapy for CKD by demonstrating consistent renal and cardiovascular protection including mortality benefit across etiologies.
Clinical Implications: Clinicians should consider finerenone in CKD management alongside ACEi/ARB and SGLT2 inhibitors when appropriate, and guideline panels should evaluate its broader incorporation; attention to monitoring and system-level access is required.
Key Findings
- Finerenone reduced kidney disease progression (kidney failure or sustained ≥57% eGFR decline) across pooled trials.
- Finerenone lowered heart failure hospitalization, cardiovascular death, and all-cause mortality with consistent effects across glycemia, eGFR, albuminuria, and etiologies.
2. Finerenone in Persons with Chronic Kidney Disease without Diabetes.
FIND-CKD, a randomized, double-blind trial of 1,584 adults with CKD but without diabetes, showed finerenone slowed the decline in eGFR versus placebo over 32 months, extending mineralocorticoid receptor antagonist benefits beyond diabetic CKD.
Impact: First high‑quality randomized trial demonstrating renal benefit of finerenone in CKD patients without diabetes, potentially expanding indications and prompting guideline/regulatory consideration.
Clinical Implications: Consideration of finerenone for non‑diabetic CKD patients to slow eGFR decline; clinicians and systems should prepare pathways for monitoring, safety, and access if guidelines adopt the indication.
Key Findings
- Randomized 1,584 adults with CKD (no diabetes) to finerenone vs placebo.
- Finerenone slowed the decline in eGFR over 32 months compared with placebo.
3. Ferroptosis promotes aortic stenosis through 5-lipoxygenase.
Mechanistic and translational work integrating human valve omics, primary cell models, two mouse in vivo models, and population replication (SCAPIS, UK Biobank) identifies the ALOX5–ACSL4 lipid peroxidation / ferroptosis axis as a central, druggable driver of calcific aortic valve disease; ALOX5 inhibition reduced valve thickening and improved hemodynamics in vivo.
Impact: Identifies a concrete, druggable pathogenic axis for calcific aortic valve disease with mechanistic depth and population-level validation — opens a translational path to medical therapies for a condition currently managed surgically.
Clinical Implications: Supports prioritizing early-phase clinical evaluation of ALOX5-/ACSL4-targeted agents and use of ferroptosis biomarkers (e.g., arachidonic acid signature) as companion diagnostics for patient selection and pharmacodynamic monitoring.
Key Findings
- ALOX5-centered lipid peroxidation is the dominant ferroptosis pathway in calcified human aortic valves.
- Targeting the ALOX5–ACSL4 axis reverses valvular lipid peroxidation/calcification in vitro and reduces valve thickening with hemodynamic improvement in vivo; arachidonic acid predicted valve calcification and incident aortic stenosis in population cohorts.